This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.
IDEXX Laboratories (IDXX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions
by Zacks Equity Research
PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.
BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting
by Zacks Equity Research
BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.
Hologic (HOLX) Partners With Gallup on Women's Health Index
by Zacks Equity Research
Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.
Abbott (ABT) Launches Telehealth Tool for Neuromodulation
by Zacks Equity Research
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes
by Zacks Equity Research
QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
Why Is Idexx (IDXX) Up 2.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.
Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF
by Zacks Equity Research
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout
by Zacks Equity Research
Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.
Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.
Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.
NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.
Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.
Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.
Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
by Zacks Equity Research
BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.